BACKGROUND: The elderly host is highly susceptible to severe disease and treatment failure in Clostridium difficile infection (CDI). We investigated how treatment with vancomycin in the aged host influences systemic and intestinal humoral responses and select intestinal microbiota. METHODS: Young (age, 2 months) and aged (age, 18 months) C57BL/6 mice were infected with VPI 10463 after exposure to broad-spectrum antibiotics. Vancomycin was given 24 hours after infection, and treatment was continued for 5 days. At select time points, specimens of serum and intestinal tissue and contents were collected for histopathologic analysis, to measure antibody levels and the pathogen burden, and to determine the presence and levels of select intestinal microbiota and C. difficile toxin. RESULTS: Levels of disease severity, relapse, and mortality were increased, and recovery from infection was slower in aged mice compared to young mice. Serum levels of immunoglobulin M, immunoglobulin A, and immunoglobulin G against C. difficile toxin A were depressed in aged mice, and vancomycin treatment reduced antibody responses in both age groups. While baseline levels of total bacterial load, Bacteroidetes, Firmicutes, and Enterobacteriaceae were mostly similar, aged mice had a significant change in the Firmicutes to Bacteroidetes ratio with vancomycin treatment. CONCLUSIONS: Vancomycin treatment decreases the systemic humoral response to CDI. Increased mortality from and recurrence of CDI in the aged host are associated with an impaired humoral response and a greater susceptibility to vancomycin-induced alteration of intestinal microbiota.
BACKGROUND: The elderly host is highly susceptible to severe disease and treatment failure in Clostridium difficile infection (CDI). We investigated how treatment with vancomycin in the aged host influences systemic and intestinal humoral responses and select intestinal microbiota. METHODS: Young (age, 2 months) and aged (age, 18 months) C57BL/6 mice were infected with VPI 10463 after exposure to broad-spectrum antibiotics. Vancomycin was given 24 hours after infection, and treatment was continued for 5 days. At select time points, specimens of serum and intestinal tissue and contents were collected for histopathologic analysis, to measure antibody levels and the pathogen burden, and to determine the presence and levels of select intestinal microbiota and C. difficile toxin. RESULTS: Levels of disease severity, relapse, and mortality were increased, and recovery from infection was slower in aged mice compared to young mice. Serum levels of immunoglobulin M, immunoglobulin A, and immunoglobulin G against C. difficile toxin A were depressed in aged mice, and vancomycin treatment reduced antibody responses in both age groups. While baseline levels of total bacterial load, Bacteroidetes, Firmicutes, and Enterobacteriaceae were mostly similar, aged mice had a significant change in the Firmicutes to Bacteroidetes ratio with vancomycin treatment. CONCLUSIONS:Vancomycin treatment decreases the systemic humoral response to CDI. Increased mortality from and recurrence of CDI in the aged host are associated with an impaired humoral response and a greater susceptibility to vancomycin-induced alteration of intestinal microbiota.
Authors: Janko Nikolich-Žugich; Gang Li; Jennifer L Uhrlaub; Kristin R Renkema; Megan J Smithey Journal: Semin Immunol Date: 2012-05-01 Impact factor: 11.130
Authors: Kevin M D'Auria; Glynis L Kolling; Gina M Donato; Cirle A Warren; Mary C Gray; Erik L Hewlett; Jason A Papin Journal: Infect Immun Date: 2013-07-29 Impact factor: 3.441
Authors: Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: Rebecca A Drummond; Jigar V Desai; Emily E Ricotta; Muthulekha Swamydas; Clay Deming; Sean Conlan; Mariam Quinones; Veronika Matei-Rascu; Lozan Sherif; David Lecky; Chyi-Chia R Lee; Nathaniel M Green; Nicholas Collins; Adrian M Zelazny; D Rebecca Prevots; David Bending; David Withers; Yasmine Belkaid; Julia A Segre; Michail S Lionakis Journal: Cell Host Microbe Date: 2022-05-13 Impact factor: 31.316
Authors: Lisa Abernathy-Close; Michael G Dieterle; Kimberly C Vendrov; Ingrid L Bergin; Krishna Rao; Vincent B Young Journal: Infect Immun Date: 2020-05-20 Impact factor: 3.441
Authors: John J Miklavcic; Thomas M Badger; Anne K Bowlin; Katelin S Matazel; Mario A Cleves; Tanya LeRoith; Manish K Saraf; Sree V Chintapalli; Brian D Piccolo; Kartik Shankar; Laxmi Yeruva Journal: J Nutr Date: 2018-11-01 Impact factor: 4.798
Authors: Jae Hyun Shin; Yingnan Gao; John H Moore; David T Bolick; Glynis L Kolling; Martin Wu; Cirle A Warren Journal: J Infect Dis Date: 2018-01-04 Impact factor: 5.226
Authors: Jocelyn M Choo; Tokuwa Kanno; Nur Masirah Mohd Zain; Lex E X Leong; Guy C J Abell; Julie E Keeble; Kenneth D Bruce; A James Mason; Geraint B Rogers Journal: mSphere Date: 2017-02-08 Impact factor: 4.389